

Hepatitis C Virus (HCV) Bibliography

October 2017

Essential Overview/Background

1. **Recommendations for Testing, Managing and Treating Hepatitis C [Internet]. AASLD, IDSA, IAS-USA. 2017. Available from: <http://www.hcvguidelines.org>. Updated September 21, 2017.**
2. A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report. National Academies of Sciences, Engineering, and Medicine. Washington, DC: The National Academies Press. 2017.
3. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. *Gastroenterology*. 2010;138(2):513–521,521. PMID: 19861128. doi: 10.1053/j.gastro.2009.09.067.
4. Eliminating the public health problem of hepatitis B and C in the United States: Phase one report National Academies of Sciences, Engineering, and Medicine. Washington, DC: The National Academies Press. 2016:1-172. Available from: [dx.doi.org/10.17226/23407](https://doi.org/10.17226/23407)
5. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. *J Hepatol*. 2014;60(2):392–420. Epub 2013 Dec 9. PMID: 24331294. doi: 10.1016/j.jhep.2013.11.003
6. Goedert JJ. Reconstruction of the hepatitis C virus epidemic in the USA. *Lancet Infect Dis*. 2016(9):1007. doi: 10.1016/S1473-3099(16)30196-7.
7. Joy JB, McCloskey RM, Nguyen T, Liang T, Khudyakov Y, Olmstead A, Kraiden M, Ward JW, Harrigan PR, Montaner JS, Poon AF. The spread of hepatitis C virus genotype 1a in North America: a retrospective phylogenetic study. *Lancet Infectious Diseases*. 2016 June;16(6):698-702. Epub 2016 Mar 30. PMID: 27039040. Available from: [dx.doi.org/10.1016/S1437-3099\(16\)00124-9](https://doi.org/10.1016/S1437-3099(16)00124-9).
8. Kim, A. Hepatitis C Virus. *Ann Intern Med*. 2016;165(5):ITC33-ITC48. doi:10.7326/AITC201609060
9. Ly KN, Hughes EM, Jiles RB, Holmberg SD. Rising Mortality Associated with Hepatitis C Virus in the United States, 2003-2013. *Clin Infect Dis*. 2016;62(10):1287-1288. Epub 2016 Mar 1. PMID: 26936668. doi: 10.1093/cid/ciw111.
10. National Viral Hepatitis Action Plan 2017-2020. *U.S. Department of Health and Human Services*. Jan 2017. Available from: <https://www.hhs.gov/sites/default/files/National%20Viral%20Hepatitis%20Action%20Plan%202017-2020.pdf>
11. The World Health Organization. Guidelines for the Screening, Care and Treatment of Persons with Hepatitis C Infection [Internet]. 2016 Apr. Available from: http://apps.who.int/iris/bitstream/10665/205035/1/9789241549615_eng.pdf?ua=1
12. Wolitski, R. Report from an Expert Consultation on the Evidence for Early Treatment of HCV in the United States. *Department of Health & Human Services*. Feb 2017. Available from: <https://www.hhs.gov/hepatitis/blog/2017/02/03/hhs-consultation-on-early-hcv-treatment.html>

HCV in Rhode Island

1. Special Section on Hepatitis C. Rhode Island Medical Journal. 2014; 97(7). ISSN 2327 – 2228.
 - a. Alexander-Scott N, Lemire A, Larson E, Bandy U. Prevention and Control of Hepatitis C in Rhode Island. *R I Med J*. 2014 Jul 1;97(7):25-28. Available from: <http://rimed.org/rimedicaljournal/2014/07/2014-07-25-hepc-alexander-scott.pdf>
 - b. Joseph R, Kofman A, Larney S, Fitzgerald P. Hepatitis C Prevention and Needle Exchange Program in Rhode Island: ENCORE. *R I Med J*. 2014 Jul 1;97(7):31-34. Available from: <http://rimed.org/rimedicaljournal/2014/07/2014-07-31-hepc-joseph.pdf>
 - c. Kinnard EN, Taylor LE, Galárraga O, Marshall BD. Estimating the true prevalence of hepatitis C in Rhode Island. *R I Med J*. 2014 Jul 1;97(7):19-24. PMID: 24983016. PMCID: PMC4349508. Available from: <http://rimed.org/rimedicaljournal/2014/07/2014-07-19-hepc-kinnard.pdf>
 - d. Taylor LE. Hepatitis C virus infection: from margin to center in Rhode Island and beyond. *R I Med J*. 2014 Jul 1;97(7):15-8. PMID: 24983015. Available from: <http://rimed.org/rimedicaljournal/2014/07/2014-07-15-hepc-taylor.pdf>
 - e. Taylor LE. What price for a cure? *R I Med J*. 2014 Jul 1;97(7):16-7. PMID: 25184174. Available from: <http://www.rimed.org/rimedicaljournal/2014/07/2014-07-15-hepc-taylor.pdf>
2. Soipe AI, Marshall BL. Prevalence of hepatitis C screening, testing, and care experience among young adults who use prescription opioids nonmedically in Rhode Island. *J Adolescent Health*. In Press.
3. Soipe AI, Razavi H, Razavi-Shearer D, Galárraga O, **Taylor LE**, Marshall BDL. Chronic hepatitis C virus (HCV) burden in Rhode Island: Modeling treatment scale-up and elimination. *Epidemiol Infect*. 2016 Aug 5:1-11. [Epub ahead of print]. PMID:27492142

HCV Policy

1. Aronsohn A, Jensen D. Distributive justice and the arrival of direct-acting antivirals: Who should be first in line? *Hepatology*. 2011;53(6):1789-1791. PMID: 21520197. doi:10.1002/hep.24374. Available from: <http://onlinelibrary.wiley.com/doi/10.1002/hep.24374/full>
2. Arora S, Kalishman S, Thornton K, Dion D, Murata G, Deming P, Parish B, Brown J, Komaromy M, Colleran K, Bankhurst A, Katzman J, Harkins M, Curet L, Cosgrove E, Pak W. Expanding access to hepatitis C virus treatment-Extension for Community Healthcare Outcomes (ECHO) project: Disruptive innovation in specialty care. *Hepatology*. 2010;52(3):1124-1133. PMID: 20607688. PMCID: PMC3795614. doi:10.1002/hep.23802. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795614/>
3. Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, Parish B, Burke T, Pak W, Dunkelberg J, Kistin M, Brown J, Jenkusky S, Komaromy M, Qualls C. Outcomes of Treatment for Hepatitis C Virus Infection by Primary Care Providers. *N Engl J Med*. 2011;364(23):2199-2207. Epub 2011 Jun 1. PMID: 21631316. PMCID: PMC3820419. doi:10.1056/nejmoa1009370. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3820419/>
4. Barua S, Greenwald R, Grebely J, Dore GJ, Swan T, Taylor LE. Restrictions for Medicaid

- Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States. *Ann Intern Med.* 2015 Aug 4;163(3):215-23. PMID: 26120969. Available from: <http://annals.org/article.aspx?articleid=2362306>
5. Casalino LP. Professionalism and Caring for Medicaid Patients: The 5% Commitment? *N Eng J Med.* 2013;369(19):1775-1777. Epub 2013 Oct 9. PMID: 24106910. doi:10.1056/nejmp1310974.
 6. Cepeda JA, Thomas DL, Astemborski J, Sulkowski MS, Kirk GD, Mehta SH. Increased mortality among persons with chronic hepatitis C with moderate or severe liver disease: a cohort study. *Clin Infect Dis.* 2017 Mar 10. doi: 10.1093/cid/cix207
 7. Chapko MK, Dufour DR, Hatia RI, Drobeniuc J, Ward JW, Teo CG. Cost-Effectiveness of Strategies for Testing Current Hepatitis C Virus Infection. *Hepatology.* 2015;62(5): 1396-1404. Epub 2015 Aug 25. PMID: 26126725. doi: 10.1002/hep.27966.
 8. Chhatwal J, Chen Q, Kanwal F. Why We Should Be Willing to Pay for Hepatitis C Treatment. *Clin Gastroenterol Hepatol.* 2015;13(10):1711-1713. Epub 2015 Jun 16. PMID: 26091736. PMCID: PMC4575858. doi:10.1016/j.cgh.2015.06.005.
 9. Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-Effectiveness and Budget Impact of Hepatitis C Virus Treatment With Sofosbuvir and Ledipasvir in the United States. *Ann Intern Med.* 2015;162(6):397. PMID: 25775312. PMCID: PMC4435698. doi:10.7326/m14-1336.
 10. Edlin B, Eckhardt B, Shu M, Holmberg S, Swan T. Toward a More Accurate Estimate of the Prevalence of Hepatitis C in the United States. *Hepatology.* 2015 Nov;62(5):1353-1363. PMID: 2729352. PMCID:PMC4897966.
 11. Edlin B. Access to Treatment for Hepatitis C Virus Infection: Time to Put Patients First. *The Lancet Infectious Diseases.* 2016 July. DOI: [http://dx.doi.org/10.1016/S1473-3099\(16\)30005-6](http://dx.doi.org/10.1016/S1473-3099(16)30005-6)
 12. Ellwood M, Greenwald R, Blankstein SF, Borowsky J, Canton A, Khan S, Villanueva A. Improving the Response to Hepatitis C Virus (HCV) in Massachusetts: Executive Summary. *SHARP: State Healthcare Access Research Project.* Apr 2013. Available at: <http://www.chlpi.org/wp-content/uploads/2014/01/SHARP-Massachusetts-Hepatitis-C-HCV-Executive-Summary.pdf>
 13. Grebely J, Dore GJ. What Is Killing People with Hepatitis C Virus Infection? *Semin Liver Dis.* 2011;31(04):331-339. Epub 2011 Dec 21. PMID: 22189973. doi:10.1055/s-0031-1297922.
 14. Grebely J, Litwin A, Dore GJ. Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all. *J Viral Hepat.* 2016; 23: 664-666. Epub 2016 Jun 8. PMID: 27272285. doi:10.1111/jvh.12550.
 15. Improving Patient Access to Hepatitis C Cures: A White Paper From the Hepatitis Therapy Access Physicians Working Group[Internet]. Hepatitis Work Group: Altice R, Charles D, Fishbein D, Gish R, Kim A, Kobayashi RH, Smith C, Striker R, Vuppalanchi R. 2015 July. Available from: http://www.ridefeatshepc.com/content/pdfs/Improving_Patient_Access_To_Hepatitis_C_Cures.pdf
 16. Jena AB, Stevens W, Gonzalez YS, Marx SE, Juday T, Lakdawalla DN, Phillipson TJ. The Wider Public Health Value of HCV Treatment Accrued by Liver Transplant Recipients. *Am J Manag Care.* 2016;22(6 Spec Issue No.):SP212-SP219. PMID: 27266951.
 17. Kanwal F, El-Serag HB. Hepatitis C Virus Treatment: The Unyielding Chasm Between Efficacy and Effectiveness. *Clin Gastroenterol Hepatol.* 2014;12(8):1381-1383. Epub 2014 Mar 4. PMID:

24607698. doi:10.1016/j.cgh.2014.02.031.

18. Kofman A, Litwin AH, Swan T, Pinkston M, Rizzo B, Bryant V, Taylor LE. Short Communication: Heterogeneity in Drug and Alcohol Use-Related Exclusion Criteria in Direct Acting Antiviral Agent Hepatitis C Treatment Trials for Individuals Coinfected with Hepatitis C Virus and HIV. *Clin Res HIV/AIDS* 2015 2(2): 1019. Available from: <http://www.jscimedcentral.com/HIV-AIDS/HIV-AIDS-2-1019.pdf>
19. Kottlil S, Wright M, Polis MA, Masur H. Treatment of Hepatitis C Virus Infection: Is It Time for the Internist to Take the Reins? *Ann Intern Med.* 2014;161(6):443. PMID: 25222390. doi:10.7326/m14-0741.
20. Lakdawalla DN, Linthicum MT, Vanderpuye-Orgle J. Does Patient Cost Sharing for HCV Drugs Make Sense? *Am J Manag Care.* 2016;22(6 Spec Issue No.):SP188-SP190. PMID: 27266947.
21. Lazarus JV, Wiktor S, Colombo M, Thursz M. Micro-elimination – A path to global elimination of hepatitis C. *J Hepatol.* In Press.
22. Levin J, Gonzalez YS, Ingram A, Lindsay C, Parise H, Virabhak S. Early versus delayed hepatitis C treatment provides increased health benefits at lower costs: A UK cost-effectiveness analysis of genotypes 1 and 4 treatment-naïve patients. Conference report at: European Association for the Study of the Liver. April 19-23, 2017. Available from: http://www.natap.org/2017/EASL/EASL_100.htm
23. Leidner AJ, Chesson HW, Xu F, Ward JW, Spradling PR, Holmberg SD. Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease. *Hepatology.* 2015;61(6):1860-1869. Epub 2015 Mar 16. PMID: 25677072. doi:10.1002/hep.27736.
24. Linthicum MT, Gonzalez YS, Mulligan K, Moreno GA, Dreyfus D, Juday T, Marx SE, Lakdawalla DN, Edlin BR, Brookmeyer R. Value of Expanding HCV Screening and Treatment Policies in the United States. *Am J Manag Care.* 2016;22(5 Spec Issue No. 6):SP227-SP235. PMID: 27266953.
25. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007. *Ann Intern Med.* 2012;156(4):271. PMID: 22351712. doi:10.7326/0003-4819-156-4-201202210-00004.
26. Moreno GA, Mulligan K, Huber C, Linthicum MT, Dreyfus D, Juday T, Marx SE, Gonzalez YS, Brookmeyer R, Lakdawalla DN. Costs and Spillover Effects of Private Insurers' Coverage of Hepatitis C Treatment. *Am J Manag Care.* 2016;22(6 Spec Issue No.):SP236-SP244. PMID: 27266954.
27. Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, Avorn J, Choudhry NK. Cost-Effectiveness of Novel Regimens for the Treatment of Hepatitis C Virus. *Ann Intern Med.* 2015;162(6):407. PMID: 25775313. doi:10.7326/m14-1152. Available from: <http://nvhr.org/sites/default/files/.users/u27/HCV%20Cost%20effective%20Najafzadeh%20Annals%202015.pdf>
28. Reau NS, Jensen DM. Sticker shock and the price of new therapies for hepatitis C: Is it worth it? *Hepatology.* 2014;59(4):1246-1249. PMID: 24493069. doi:10.1002/hep.27039. Available from: <http://onlinelibrary.wiley.com/doi/10.1002/hep.27039/full>
29. Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons Born During 1945-1965. Morbidity and Mortality Weekly Report [Internet]. Centers for Disease Control and Prevention. 2012 Aug;61(4). Available from:

<http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6104a1.htm>

30. Rein DB, Wittenborn JS, Smith BD, Liffmann DK, Ward JW. The Cost-effectiveness, Health Benefits, and Financial Costs of New Antiviral Treatments for Hepatitis C Virus. *Clin Infect Dis*. 2015;61(2):157-168. Epub 2015 Mar 16. PMID: 25778747. doi:10.1093/cid/civ220. Available from: http://nvhr.org/sites/default/files/.users/u27/Clin%20Infect%20Dis.-2015-Rein-cid_civ220%281%29.pdf
31. Saag MS. Editorial Commentary: Getting Smart in How We Pay for HCV Drugs: KAOS vs CONTROL. *Clin Infect Dis*. 2015;61(2):169-170. Epub 2015 Mar 16. PMID: 25778748. doi:10.1093/cid/civ221. Available from: http://nvhr.org/sites/default/files/.users/u27/Clin%20Infect%20Dis.-2015-Saag-cid_civ221.pdf
32. Tsochatzis EA, Crossan C, Longworth L, Gurusamy K, Rodriguez-Peralvarez M, Mantzoukis K, O'Brien J, Thalassinos E, Papastergiou V, Noel-Storr A, Davidson B, Burroughs AK. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. *Hepatology*. 2014;60(3):832-843. Epub 2014 Jul 29. PMID: 25043847. PMCID: PMC4265295. doi:10.1002/hep.27296.
33. Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. *Hepatology*. 2009;50(6):1750-1755. PMID: 19824079. doi:10.1002/hep.23220. Available from: <http://onlinelibrary.wiley.com/doi/10.1002/hep.23220/full>
34. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating Future Hepatitis C Morbidity, Mortality, and Costs in the United States. *Am J Public Health*. 2000;90(10):1562-1569. PMID: 11029989. doi:10.2105/ajph.90.10.1562. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1446368/pdf/11029989.pdf>

HCV Screening

1. Boschert S. Best HCV value? Screen All Baby Boomers, Treat All. *Internal Medicine News*. 2014 Dec:19-21. Available from: <http://www.pm360online.com/best-hcv-value-screen-all-baby-boomers-treat-all-infections/>
2. Coffin PO, Reynolds A. Ending hepatitis C in the United States: the role of screening. *Hepat Med*. 2014(6):79-87. PMID: 25114602. PMCID: PMC4086667. doi:10.2147/hmer.s40940. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086667/>
3. Coffin PO, Scott JD, Golden MR, Sullivan SD. Cost-effectiveness and Population Outcomes of General Population Screening for Hepatitis C. *Clin Infect Dis*. 2012;54(9):1259-1271. Epub 2012 Mar 12. PMID: 22412061. PMCID: PMC3404694. doi:10.1093/cid/cis011. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404694/>
4. Frieman JM, Tran TM, Schumacher SG, White LF, Ongarello S, Cohn J, Easterbrook PJ, Linas BP, Denkinger CM. Hepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virus Infection: A Systematic Review and Meta-analysis. *Ann Intern Med*. 2016;165(5):345-355. Epub 2016 Jun 21. PMID: 27322622. doi: 10.7326/M16-0065.
5. Jonas MC, Rodriguez CV, Redd J, Sloane DA, Winston BJ, Loftus BC. Streamlining Screening to Treatment: The Hepatitis C Cascade of Care at Kaiser Permanente Mid-Atlantic States. *Clin Infect Dis*. 2016;62: 1290-1296. Available from: <http://www.natap.org/2016/HCV/Clin2016-Jonas12906.pdf>

6. Koretz RL, Lin KW, Ioannidis JP, Lenzer J. Is widespread screening for hepatitis C justified? *BMJ*. 2015;350:g7809-g7809. PMID: 25587052. doi:10.1136/bmj.g7809. Available from: <http://www.pm360online.com/best-hcv-value-screen-all-baby-boomers-treat-all-infections/>
7. Lushniak BD. Surgeon General's Perspectives. *Public Health Rep*. 2014;129(3):220-221. PMID: PMC3982548. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3982548/>.
8. Moyer VA; U.S. Preventive Services Task Force. Screening for Hepatitis C Virus Infection in Adults: U.S. Preventive Services Task Force Recommendation Statement. *Ann Intern Medicine*. 2013;159(5):349. PMID: 23798026. doi:10.7326/0003-4819-159-5-201309030-00672.
9. Ngo-Metzger Q, Ward JW, Valdiserri RO. Expanded Hepatitis C Virus Screening Recommendations Promote Opportunities for Care and Cure. *Ann Intern Med*. 2013;159(5):364. PMID: 23797155. doi:10.7326/0003-4819-159-5-201309030-00675. Available from <http://annals.org/article.aspx?articleid=1700384>
10. Smith BD, Yartel AK, Krauskopf K, Massoud OI, Brown KA, Fallon MB, Rein DB. Hepatitis C Virus Antibody Positivity and Predictors Among Previously Undiagnosed Adult Primary Care Outpatients: Cross-Sectional Analysis of a Multisite Retrospective Cohort Study. *Clin Infect Dis*. 2015;60(8):1145-1152. Epub 2015 Jan 16. PMID: 25595745. doi:10.1093/cid/civ002. Available from: <http://cid.oxfordjournals.org/content/60/8/1145.long>
11. Taylor LE, Foont JA, DeLong AK, Wurcel A, Linas BP, Chapman S, Maynard MA, Cu-Uvin S, Mayer KH. The spectrum of undiagnosed hepatitis C virus infection in a US HIV clinic. *AIDS Patient Care STDS*. 2014 Jan;28(1):4-9. PMID: 24428794. doi:10.1089/apc.2013.0130. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894677/>

HCV and People who Inject Drugs (PWID)

1. Arain A, Robaey G. Eligibility of persons who inject drugs for treatment of hepatitis C virus infection. *World J Gastroenterol*. 2014;20(36):12722. PMID: 25278674. PMID: PMC4177459. doi:10.3748/wjg.v20.i36.12722.
2. Batchelder AW, Peyser D, Nahvi S, Amsten JH, Litwin AH. "Hepatitis C treatment turned me around." Psychological and behavioral transformation related to hepatitis C treatment. *Drug Alcohol Depend*. 2015;153:66-71. Epub 2015 Jun 9. PMID: 26096534. PMID: PMC4759650. doi: 0.1016/j.drugalcdep.2015.06.007.
3. Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng CY, Conway B, Grebely J, Howe AY, Gendrano IN, Chen E, Huang HC, Dutko FJ, Nickle DC, Nguyen BY, Wahl J, Barr E, Robertson MN, Platt HL; C-EDGE CO-STAR Study Group. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy. *Ann Intern Med*. 2016. PMID: 27537841. doi: 10.7326/M16-0816.
4. Dore GJ, Hellard M, Matthews GV, Grebely J, Haber PS, Petoumenos K, Yeung B, Marks P, van Beek I, McCaughan G, White P, French R, Rawlinson W, Lloyd AR, Kaldor JM; Australian Trial In Acute Hepatitis C Study Group. Effective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus Infection. *Gastroenterology*. 2010;138(1):123-135.e2. PMID: 19782085. PMID: PMC2813391. doi:10.1053/j.gastro.2009.09.019. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2813391/>
5. Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD, Lo B. Is It Justifiable to

- Withhold Treatment for Hepatitis C from Illicit-Drug Users? *N Engl J Med.* 2001;345(3):211-214. PMID: 11463019. PMCID: PMC1510901. doi:10.1056/nejm200107193450311. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1510901/>
6. Edlin BR, Winkelstein ER. Can hepatitis C be eradicated in the United States? *Antiviral Res.* 2014;110:79-93. PMID: 25110202. doi:10.1016/j.antiviral.2014.07.015.
 7. Edlin BR, Winkelstein ER. Unanswered Questions: A Research Agenda for Hepatitis C Eradication. Supplement to can hepatitis C be eradicated in the United States? *Antiviral Res.* 2014 Oct 7;110. doi:10.1016/j.antiviral.2014.07.015.
 8. Garfein RS, Golub ET, Greenberg AE, Hagan H, Hanson DL, Hudson SM, Kapadia F, Latka MH, Ouellet LJ, Purcell DW, Strathdee SA, Thiede H; DUIT Study Team. A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. *AIDS.* 2007;21(14):1923-1932. PMID: 17721100. doi:10.1097/qad.0b013e32823f9066.
 9. Goedert, JJ. Reconstruction of the hepatitis C virus epidemic in the USA. *Lancet Infectious Diseases.* 2016;16(9):1007. doi: [http://dx.doi.org/10.1016/S1473-3099\(16\)30196-7](http://dx.doi.org/10.1016/S1473-3099(16)30196-7).
 10. Grebely J, Dore GJ. Can hepatitis C virus infection be eradicated in people who inject drugs? *Antiviral Res.* 2014;104:62-72. PMID: 24468275. doi:10.1016/j.antiviral.2014.01.002.
 11. Grebely J, Dore GJ, Zeuzem S, Aspinall RJ, Fox R, Han L, McNally J, Osinusi A, Brainard DM, Subramanian GM, Natha M, Foster GR, Mangia A, Sulkowski M, Feld JJ. Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials. *Clin Infect Dis.* 2016;63(11):1479-1481. doi: 10.1093/cid/ciw579.
 12. Grebely J, Haire B, Taylor LE, Macneill P, Litwin AH, Swan T, Byrne J, Levin J, Bruggmann P, Dore GJ; International Network for Hepatitis in Substance Users. Excluding people who use drugs or alcohol from access to hepatitis C treatments - Is this fair, given the available data? *J Hepatol.* 2015 Oct;63(4):779-82. Epub 2015 Aug 4. PMID: 26254264. doi:10.1016/j.jhep.2015.06.014.
 13. Grebely J, Oser M, Taylor LE, Dore GJ. Breaking down the barriers to hepatitis C virus (HCV) treatment among individuals with HCV/HIV coinfection: action required at the system, provider, and patient levels. *J Infect Dis.* 2013 Mar;207 Suppl 1:S19-25. PMID: 23390301 PMCID: PMC3565594. Available from: http://jid.oxfordjournals.org/content/207/suppl_1/S19.full
 14. Grebely J, Robaey G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Llyod AR, Mauss S, Prins M, Swan T, Schaefer M, Tatlor LE, Dore GJ; International Network for Hepatitis in Substance Users. Recommendations for the management of hepatitis C virus infection among people who inject drugs. *Int J Drug Policy.* 2015;26(10):1028-1038. PMID: 26282715. doi:10.1016/j.drugpo.2015.07.005.
 15. Harris KA Jr, Arnsten JH, Litwin AH. Successful Integration of Hepatitis C Evaluation and Treatment Services With Methadone Maintenance. *J Addic Med.* 2010;4(1):20-26. PMID: 20485532. PMCID: PMC2872238. doi:10.1097/adm.0b013e3181add3de. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2872238/>
 16. Hellard M, Sacks-Davis R, Gold J. Hepatitis C Treatment for Injection Drug Users: A Review of

- the Available Evidence. *Clin Infect Dis*. 2009;49(4):561-573. PMID: 19589081. doi:10.1086/600304. Available from: <http://cid.oxfordjournals.org/content/49/4/561.long>
17. Higgs P, Sacks-Davis R, Gold J, Hellard M. Barriers to receiving hepatitis C treatment for people who inject drugs: Myths and evidence. *Hepat Mon*. 2011;11(7):513. PMID: PMC3212767. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3212767/>
 18. Jürgens R, Csete J, Amon JJ, Baral S, Beyrer C. People who use drugs, HIV, and human rights *Lancet Infectious Diseases*. 2010;376(9739):475-485. PMID: 20650514. doi:10.1016/s0140-6736(10)60830-6.
 19. Litwin AH, Harris KA Jr., Nahvi S, Philippe J, Zamor MD, Soloway IJ, Tenore PL, Kaswan D, Gourevitch MN, Arnsten JH. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. *J Sub Abuse Treat*. 2009;37(1):32-40. PMID: PMC2692471. doi:10.1016/j.jsat.2008.09.009. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2692471/>
 20. Litwin AH, Soloway I, Gourevitch MN. Integrating Services for Injection Drug Users Infected with Hepatitis C Virus with Methadone Maintenance Treatment: Challenges and Opportunities. *Clin Infect Dis*. 2005;40(s5):S339-S345. PMID: 15768345. doi:10.1086/427450. Available from: http://cid.oxfordjournals.org/content/40/Supplement_5/S339.long
 21. Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, Foster Gr, Dillon JF, Goldberg DJ, Dore GJ, Hickman M. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. *Hepatology*. 2013;58(5):1598-1609. PMID: 23553643. PMID: PMC3933734. doi:10.1002/hep.26431. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933734/>
 22. Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. *Hepatology*. 2011;55(1):49-57. PMID: 21898506. doi:10.1002/hep.24656. Available from: <http://onlinelibrary.wiley.com/doi/10.1002/hep.24656/full>
 23. Masson CL, Delucchi KL, McKnight C, Hettema J, Khalili, Min A, Jordan AE, Pepper N, Hall J, Hengl NS, Young C, Shopshire MS, Manuel JK, Coffin L, Hammer H, Shapiro B, Seewald RM, Bodenheimer HC Jr, Sorenson JL, Des Jarlais DC, Perlman DC. A Randomized Trial of a Hepatitis Care Coordination Model in Methadone Maintenance Treatment. *Am J Public Health*. 2013;103(10):e81-e88. PMID: 23947319. PMID: PMC3853128. doi:10.2105/ajph.2013.301458. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853128/>
 24. Stein, MR, Soloway IJ, Jefferson KS, Roose RJ, Arnsten JH, Litwin AH. Concurrent group treatment for hepatitis C: Implementation and outcomes in a methadone maintenance treatment program. *J Substance Abuse Treatment*. 2012;43(4):424-432. doi: 10.1016/j.jsat.2012.08.007.
 25. Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?. *Addiction*. 2004;99(9):1167-1175. PMID: 15317637. doi:10.1111/j.1360-0443.2004.00821.x.
 26. Sylvestre DL, Litwin AH, Clements BJ, Gourevitch MN. The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. *J Sub Abuse Treat*. 2005;29(3):159-165. PMID: 16183464. doi:10.1016/j.jsat.2005.06.002.
 27. Sylvestre DL, Zweben JE. Integrating HCV services for drug users: A model to improve

- engagement and outcomes. *Int J Drug Policy*. 2007;18(5):406-410. PMID: 17854729. doi:10.1016/j.drugpo.2007.01.010.
28. Taylor LE, Bowman SE, Chapman S, Zaller N, Stein MD, Cioe P, Maynard M, McGovern BH. Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy. *Drug Alcohol Depend*. 2011 Jul 1;116(1-3):233-7. Epub 2010 Dec 21. PMID: 21177046. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4212315/>
 29. Treloar C, Rance J, Dore GJ, Grebely J; ETHOS Study Group. Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study. *J Viral Hepat*. 2013;21(8):560-567. PMID: 24299222. doi:10.1111/jvh.12183.
 30. *Clinical Infectious Diseases*. 2013;57(Suppl. 2). Full supplement available from: http://cid.oxfordjournals.org/content/57/suppl_2.toc
 - a. Alavi M, Grebely J, Micallef M, Dunlop AJ, Balcomb AC, Day CA, Treloar C, Bath N, Haber PS, Dore GJ; Enhancing Treatment for Hepatitis C in Opioid Substitution Settings (ETHOS) Study Group. Assessment and Treatment of Hepatitis C Virus Infection Among People Who Inject Drugs in the Opioid Substitution Setting: ETHOS Study. *Clin Infect Dis*. 2013;57(suppl 2):S62-S69. PMID: 23884068. doi:10.1093/cid/cit305.
 - b. Aspinall EJ, Corson S, Doyle JS, Grebely J, Hutchinson SJ, Dore GJ, Goldbery DJ, Hellard ME. Treatment of Hepatitis C Virus Infection Among People Who Are Actively Injecting Drugs: A Systematic Review and Meta-analysis. *Clin Infect Dis*. 2013;57(suppl 2):S80-S89. PMID: 23884071. doi:10.1093/cid/cit306.
 - c. Bruggmann P, Litwin AH. Models of Care for the Management of Hepatitis C Virus Among People Who Inject Drugs: One Size Does Not Fit All. *Clin Infect Dis*. 2013;57(suppl 2):S56-S61. PMID: 23884067. doi:10.1093/cid/cit271.
 - d. Cox AL, Thomas DL. Hepatitis C Virus Vaccines Among People Who Inject Drugs. *Clin Infect Dis*. 2013;57(suppl 2):S46-S50. PMID: 23884065. PMID: PMC3722079. doi:10.1093/cid/cit329.
 - e. Crawford S, Bath N. Peer Support Models for People With a History of Injecting Drug Use Undertaking Assessment and Treatment for Hepatitis C Virus Infection. *Clin Infect Dis*. 2013;57(suppl 2):S75-S79. PMID: 23884070. doi:10.1093/cid/cit297.
 - f. Grady BP, Schinkel J, Thomas XV, Dalgard O. Hepatitis C Virus Reinfection Following Treatment Among People Who Use Drugs. *Clin Infect Dis*. 2013;57(suppl 2):S105-S110. PMID: 23884057. doi:10.1093/cid/cit301.
 - g. Grebely J, Bruggmann P, Backmund M, Dore GJ. Moving the Agenda Forward: The Prevention and Management of Hepatitis C Virus Infection Among People Who Inject Drugs. *Clin Infect Dis*. 2013;57(suppl 2):S29-S31. doi:10.1093/cid/cit264.
 - h. Hilsden RJ, Macphail G, Grebely J, Conway B, Lee SS. Directly Observed Pegylated Interferon Plus Self-Administered Ribavirin for the Treatment of Hepatitis C Virus Infection in People Actively Using Drugs: A Randomized Controlled Trial. *Clin Infect Dis*. 2013;57(suppl 2):S90-S96. PMID: 23884072. doi:10.1093/cid/cit327.
 - i. Martin NK, Hickman M, Hutchinson SJ, Goldberg DJ, Vickerman P. Combination Interventions to Prevent HCV Transmission Among People Who Inject Drugs: Modeling the Impact of Antiviral Treatment, Needle and Syringe Programs, and Opiate Substitution

Therapy. *Clin Infect Dis*. 2013;57(suppl 2):S39-S45. doi:10.1093/cid/cit296.

- j. Mauss S, Klinker H. Drug-Drug Interactions in the Treatment of HCV Among People Who Inject Drugs. *Clin Infect Dis*. 2013;57(suppl 2):S125-S128. PMID: 23884060. doi:10.1093/cid/cit299.
- k. Page K, Morris MD, Hahn JA, Maher L, Prins M. Injection Drug Use and Hepatitis C Virus Infection in Young Adult Injectors: Using Evidence to Inform Comprehensive Prevention. *Clin Infect Dis*. 2013;57(suppl 2):S32-S38. PMID: 23884063. PMCID: PMC3722077. doi:10.1093/cid/cit300.
- l. Post JJ, Arain A, Lloyd AR. Enhancing Assessment and Treatment of Hepatitis C in the Custodial Setting. *Clin Infect Dis*. 2013;57(suppl 2):S70-S74. PMID: 23884069. doi:10.1093/cid/cit265.
- m. Reimer J, Schmidt CS, Schulte B, Gansefort D, Gözl J, Gerken G, Scherbaum N, Verthein U, Backmund M. Psychoeducation Improves Hepatitis C Virus Treatment During Opioid Substitution Therapy: A Controlled, Prospective Multicenter Trial. *Clin Infect Dis*. 2013;57(suppl 2):S97-S104. PMID: 23884073. doi:10.1093/cid/cit307.
- n. Robaey G, Grebely J, Mauss S, Bruggmann P, Moussalli J, De Gottardi A, Swan T, Arain A, Kautz A, Stöver H, Wedemeyer H, Schaefer M, Taylor LE, Backmund M, Dalgard O, Prins M, Dore GJ; International Network on Hepatitis in Substance Users. Recommendations for the Management of Hepatitis C Virus Infection Among People Who Inject Drugs. *Clin Infect Dis*. 2013;57(suppl 2):S129-S137. PMID: 23884061. doi:10.1093/cid/cit302.
- o. Schaefer M, Sarkar R, Diez-Quevedo C. Management of Mental Health Problems Prior to and During Treatment of Hepatitis C Virus Infection in Patients With Drug Addiction. *Clin Infect Dis*. 2013;57(suppl 2):S111-S117. PMID: 23884058. doi:10.1093/cid/cit266.
- p. Taylor LE, Swan T, Matthews GV. Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy. *Clin Infect Dis*. 2013 Aug;57 Suppl 2:S118-24. PMID: 23884059. doi:10.1093/cid/cit326.
- q. Treloar C, Rance J, Backmund M. Understanding Barriers to Hepatitis C Virus Care and Stigmatization From a Social Perspective. *Clin Infect Dis*. 2013;57(suppl 2):S51-S55. PMID: 23884066. doi:10.1093/cid/cit263.

HCV and Alcohol Use

1. Anand BS, Currie S, Dieperink E, Bini EJ, Shen H, Ho SB, Wright T, VA-HCV-001 Study Group. Alcohol Use and Treatment of Hepatitis C Virus: Results of a National Multicenter Study. *Gastroenterology*. 2006;130(6):1607-1616. PMID: 16697724. doi:10.1053/j.gastro.2006.02.023.
2. Bruggmann P, Dampz M, Gerlach T, Kravec L, Falcato L. Treatment outcome in relation to alcohol consumption during hepatitis C therapy: An analysis of the Swiss Hepatitis C Cohort Study. *Drug and Alcohol Dependence*. 2010;110(1-2):167-171. PMID: 20334985. doi:10.1016/j.drugalcdep.2010.02.016.
3. Corrao G, Aricò S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. *Hepatology*. 1998;10(9):815. PMID: 9537428. doi:10.1097/00042737-199809000-00019.
4. Hutchinson SJ, Bird SM, Goldberg DJ. Influence of Alcohol on the Progression of Hepatitis C Virus Infection: A Meta-analysis. *Clin Gastroenterol and Hepat*. 2005;3(11):1150-1159. PMID:

16271348. doi:10.1016/s1542-3565(05)00407-6. Available from:
<http://onlinelibrary.wiley.com/doi/10.1002/hep.510270404/epdf>

5. Le Lan C, Guillygomarc'h A, Danielou H, Le Dréau G, Lainé F, Védeilhé C, Deugnier Y, Brissot P, Guyader D, Moirand R. A multi-disciplinary approach to treating hepatitis C with interferon and ribavirin in alcohol-dependent patients with ongoing abuse. *J Hepat.* 2012;56(2):334-340. PMID: 21756854. doi:10.1016/j.jhep.2011.05.021.
6. Rosman AS, Waraich A, Galvin K, Casiano J, Paronetto F, Lieber CS. Alcoholism is Associated with Hepatitis C but not Hepatitis B in an Urban Population. *Am J Gastroenterol.* Mar 1996;91(3):498-505. PMID: 8633498.
7. Singal AK, Anand BS. Mechanisms of Synergy Between Alcohol and Hepatitis C Virus. *J Clin Gastroenterol.* 2007;41(8):761-772. PMID: 17700425. doi:10.1097/mcg.0b013e3180381584.

HCV/HIV Coinfection

1. Freiman JM, Huang W, White LF, Geng EH, Hurt CB, Taylor LE, Overton ET, Cachay ER, Kitahata MM, Moore RD, Rodriguez B, Mayer KH, Linas BP. Current Practices of Screening for Incident Hepatitis C Virus (HCV) Infection Among HIV-Infected, HCV-Uninfected Individuals in Primary Care. *Clin Infect Dis.* 2014;59(12):1686-1693. doi:10.1093/cid/ciu698.
2. Garg S, Taylor LE, Grasso C, Mayer KH. Prevalent and incident hepatitis C virus infection among HIV-infected men who have sex with men engaged in primary care in a Boston community health center. *Clin Infect Dis.* 2013 May;56(10):1480-7. Epub 2013 Feb 5. PMID: 23386630. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3634307/>
3. Graham C. Hepatitis C and HIV Co-infection. *Journal of the American Medical Association.* 2015;313(12):1217. doi:10.1001/jama.2015.1111.
4. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents: Considerations for Antiretroviral Use in Patients with Coinfections [Internet]. U.S. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents- A Working Group of the Office of AIDS Research Advisory Council (OARAC). 2014 Nov. Available from: <https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf>
5. Taylor LE, Holubar M, Wu K, Bosch RJ, Wyles DL, Davis JA, Mayer KH, Sherman KE, Tashima KT. Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials. *Clin Infect Dis.* 2011 Mar 15;52(6):812-8. Epub 2011 Jan 31. PMID: 21282184. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3106260/>
6. Taylor LE, Swan T, Matthews GV. Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy. *Clin Infect Dis.* 2013 Aug;57 Suppl 2:S118-24. PMID: 23884059. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3722078/>
7. Taylor LE, Swan T, Mayer KH. HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. *Clin Infect Dis.* 2012 Jul;55 Suppl 1:S33-42. PMID: 22715212. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491862/>
8. Taylor LE. HIV/viral hepatitis coinfection: the Immunology Center experience. *Med Health R.I.* 2009 Jul;92(7):234-6. PMID: 19685638. Available from: <http://www.rimed.org/medhealthri/2009-07/2009-07-234.pdf>
9. Training and Implementing Guide: Delivering Hepatitis C Treatment in an HIV Care Setting [Internet]. U.S. Department of Health and Human Services Health Resources and Services

Administration HIV/AIDS Bureau, Special Projects of National Significance Program. 2014 Sep. Available from: https://careacttarget.org/sites/default/files/file-upload/resources/HepC_v7.pdf

Evaluating Fibrosis

1. Berenguer J, Zamora FX, Aldámiz-Echevarría T, Von Wichmann MA, Crespo M, López-Aldeguer J, Carrero A, Montes M, Quereda C, Téllez MJ, Galindo MJ, Sanz J, Santos I, Guardiola JM, Barros C, Ortega E, Pulido F, Rubio R, Mallolas J, Tural C, Jurdado JJ, Pérez G, Díez C, Álvarez-Pellicer J, Esteban H, Bellón JM, González-García J; Grupo de Estudio del SIDA (GESIDA) HIV/HCV Cohort Study Group. Comparison of the Prognostic Value of Liver Biopsy and FIB-4 Index in Patients Coinfected With HIV and Hepatitis C Virus. *Clin Infect Dis*. 2014;60(6):950-958. Epub 2014 Nov 24. PMID: 25422386. doi:10.1093/cid/ciu939.
2. Holmberg SD, Lu M, Rupp LB, Lamerato LE, Moorman AC, Vijayadeva V, Boscarino JA, Henkle EM, Gordon SC; Chronic Hepatitis Cohort Study (CHeCs) Investigators. Noninvasive Serum Fibrosis Markers for Screening and Staging Chronic Hepatitis C Virus Patients in a Large US Cohort. *Clin Infect Dis*. 2013;57(2):240-246. Epub 2013 Apr 16. PMID: 23592832. doi:10.1093/cid/cit245.
3. Smith DJ, Combellick J, Jordan AE, Hagan H. Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis. *Int J Drug Policy*. 2015;26(10):911-921. Epub 2015 Jul 26. PMID: 26298331. PMCID: PMC4577462. doi:10.1016/j.drugpo.2015.07.004.

HCV and Cirrhosis

1. Ge PS, Runyon BA. Serum Ammonia Level for the Evaluation of Hepatic Encephalopathy. *JAMA*. 2014;312(6):643-644.
2. Yadav A, Vargas HE. Care of the patient with cirrhosis. *Clinical Liver Disease*. 2015;5(4):100-104. doi:10.1002/cld.462.

Vetted Websites

- <http://ridefeatshepc.com/>
- <http://www.cdc.gov/hepatitis/hcv/>
- <http://www.who.int/hepatitis/en/>
- <http://www.treatmentactiongroup.org/hcv>
- <http://www.natap.org/>
- <http://hcvadvocate.org/>
- <http://www.oasiscliniconline.org/>
- <http://www.hivandhepatitis.com/>
- <http://nvhr.org/>
- <http://www.hepeducation.org/>
- <http://hcvtreatmentaccess.org/>